Key Takeaways
- Revenue miss, not a demand miss: INR15 crores of Q4 revenue shifted into Q1 FY26 on a packaging-line glitch and a partner launch delay, not lost. Management still targets 50%+ top-line growth for FY26.
- ANDA portfolio nearly doubled: The acquisition of 14 ANDAs from Dr. Reddy's and 1 from Breckenridge takes the total to 61 products, with commercial launches beginning Q3 FY26.
- Profitability leap promised: FY26 PAT is guided to at least double on an absolute basis, while EBITDA margin is held at 24–26% and called "100% sustainable."
- Tariff risk structurally contained: A US FDA-approved plant in the US, 6–9 months of API inventory, and only one China-sourced product (with two years of API on hand) insulate the business.
- What to watch next quarter: Whether the shifted INR15 crores actually lands, the pace of the 31 planned ANDA launches, and any inorganic deal announcement.
Revenue Bridge: The INR15 Crore Shift
- Packaging-line delay: A track-and-trace compatibility issue on a bottle-packaging line held up shipment from March to April, pushing revenue into Q1 FY26.
- Partner launch delay: A marketing partner postponed a product launch by 15–20 days; that launch is now scheduled imminently.
- No demand-side weakness cited: Management attributed the shortfall entirely to these two operational timing issues, not to any softening in end-market demand or order book.
Regulated Markets: ANDA Portfolio Build-Out
- Acquired portfolio: 14 ANDAs from Dr. Reddy's and 1 from Breckenridge added, taking the total to 61. Commercial launches from the acquired set begin Q3 FY26 in a phased manner.
- Launch cadence: 31 ANDA products planned for launch in FY26 across the regulated market, with approvals expected around the September-October window, making H2 the heavier half.
- Own-ANDA model: Products are sold by large distribution or pharma companies under their respective brands; Senores earns via licensing, COGS-plus-margin, and profit share. Some existing commercial products now hold larger market share than in prior quarters.
- CDMO-CMO traction: 23 CDMO-CMO product launches planned for FY26. The USP is handling customers from product idea through to launch, with multi-geography presence as a competitive edge. One product was added last quarter.
Shah: "So we literally handled our customer right from the product idea to launch of a product, So that's our USP. And being multi-geographically present, this really gives us an edge compared to all other competitors that exist in the marketplace."
Tariff & Supply-Chain Insulation
- US manufacturing footprint: A US FDA-approved facility in the US means the company is "buying in US, selling in US," structurally insulating it from cross-border tariff exposure.
- API inventory buffer: 6–9 months of API inventory is held, and only one product is sourced from China, for which two years of API supply is already on hand.
- Equalization tariff nuance: Management noted that equalization tariffs are hard to apply because US products use bottle packaging while European products use blister packaging, making them non-equivalent at the SKU level.
Majmudar: "I am a US company, manufacturing in US, buying in US, selling in US. So to that extent, it doesn't matter."
Emerging Markets: Margin Inflection Story
- Turnaround trajectory: The emerging-markets business was PAT-negative, cash-flow-negative, and EBITDA-negative when acquired in 2021. It has since turned EBITDA-positive, reaching lower-single-digit EBITDA last year, with registrations more than doubling over the same period.
- Margin targets: EBITDA margin reached 7% this year and is expected to move close to double digits next year, with a two-year target of 15–16%. The improvement is driven by a shift toward niche molecules, changed go-to-market strategies, and new product approvals improving the mix and per-unit production cost, with no additional capex required.
- Registration pipeline: 48 products registered in Q4 FY25, 9 more filed. The target is 650+ registered products across all emerging markets by end of FY27, with registrations expected to double next year from current levels.
Capacity Expansion & Backward Integration
- Oral solids: Two lines are already operational, a third is being installed, and a fourth is being planned, setting up for sizable volume output.
- New API facility: A 100–120 metric-ton facility commenced production in March and will begin commercial billing from next month. The US FDA trigger is expected in Q2 CY26, after which backward integration for the US business begins with one existing product. Pre-FDA, multiple discussions are underway to utilize current capacity.
- Injectable capex: Planned for end of this year, after the oral solids expansion progresses.
- India domestic business: Management is "aggressively looking at expansion" and expects to finalize land soon. Branded generics in India are seeing roughly 100% month-over-month growth and are approved in 100–120-plus countries.
Margins & Profitability
- EBITDA margin guidance: 24–26% on an annual basis, called "100% sustainable" and expected to "only improve."
- PAT guidance: At least 100% growth in absolute PAT (after minority interest) on a full-year basis for FY26. Margins will improve, though the exact extent is not quantified.
- Employee cost normalization: Q4 employee costs declined YoY because the prior year included extra shifts and additional contractual labor; new hires for expansion will bring costs back to original levels.
- Working capital: FY24 is not strictly comparable due to staggered consolidation of businesses. Per management, 100–190 days of receivables in the US is "quite okay" for the model.
Majmudar: "It will only improve. 100% sustainable."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Top-line growth | At least 50%+ year-on-year | FY26 full year |
| PAT growth | At least 100% year-on-year (after minority interest) | FY26 full year |
| EBITDA margin | Maintain 24–26% range | Annual basis, FY26 |
| ANDA launches | 31 products in regulated market | FY26 |
| CDMO-CMO launches | 23 products | FY26 |
| Acquired ANDA commercial launches | Phased launches of Dr. Reddy's portfolio | Beginning Q3 FY26 |
| Emerging market registrations | 650+ registered products across all emerging markets | By end of FY27 |
| Emerging market EBITDA margin | Move close to double digits; 15–16% target | Next year; within two years |
| API facility US FDA trigger | File and trigger inspection | Q2 CY26 |
| Injectable capex | Begin investment | End of current year |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹410 cr (FY25), +91% YoY |
| Regulated market revenue | ₹64 cr, +17% YoY |
| Emerging market revenue | ₹37 cr |
| Consolidated EBITDA | ₹102 cr (FY25), +145% YoY |
| EBITDA margin | 25% (FY25), +540 bps YoY |
| Regulated market EBITDA margin | upwards of 40% |
| Emerging market EBITDA margin | 7% (FY25) |
| Consolidated PAT after minority interest | ₹59 cr (FY25), +86% YoY |
| PAT growth guidance | ~100% (FY26), in absolute terms |
| Revenue growth guidance | at least 50% plus (FY26) |
| Revenue mix guidance | ~70% regulated, ~30% emerging, steady-state annualized |
| Commercialized ANDA portfolio | 22 as of March 31, 2025 |
| Total ANDA portfolio | 61 |
| CDMO-CMO portfolio | 22 products |
| CDMO-CMO pipeline | 69 products as of March 2025 |
| Emerging market registered products | 285 as of March 31, 2025 |
| Emerging market portfolio target | 650+ registered products by end FY27 |
| Products expected to launch in FY26 | 31 ANDA products in regulated market, 23 CDMO-CMO products |
| Revenue shifted from Q4 to Q1 | ₹15 cr anticipated revenue not realized in Q4 |
| Trade receivables days | 108 days, reduced from 228 days in FY24 |
| Inventory days | 43 days, reduced from 69 days in FY24 |
| R&D expenses | ₹3.5 cr total debited to P&L |
| Capex planned for FY26 | ₹250 cr |
| Ratnatris Pharmaceuticals full-year revenue | ₹121 cr |